The global Pheochromocytoma market garnered revenue around USD XX Billion in 2019 and projected to reach USD 2 Billion in 2027, with at a compound annual growth rate of 3.85% throughout the estimate period from 2020 to 2027.
Pheochromocytoma is a rare type of hormone-secreting tumor that develops in the adrenal gland. Approximately 5% of all adrenal gland tumors are pheochromocytoma. The tumor is usually benign and hence does not cause cancer in most of the cases. Only 10% of the pheochromocytomas have chances to become cancerous. This adrenal gland tumor secretes the catecholamine hormones that may cause either episodic or persistent high blood pressure.
The condition is similar to adrenal paraganglioma. It arises from the chromaffin cells. Approximately 25% to 35% of cases of pheochromocytoma can be due to genetic disruptions or mutations to certain genes. The rising prevalence of pheochromocytoma and increase research and development for the development of specific treatment options for the condition is expected to drive the market growth.
An increasing number of drugs in the clinical trials are positively influencing the market growth. These drugs are cabozantinib by Exelixis, Inc., zebra by Progenics Pharmaceuticals, Inc., and Lutathera by Advanced Accelerator Applications, among others.
Increasing investment by major companies to develop specific treatment options
High prevalence of pheochromocytoma
The growing number of clinical trials for drugs to treat pheochromocytoma
Rapidly changing lifestyle
Rising healthcare expenditure
Increasing incidence rate of rare tumors
Stringent government regulations
Lack of availability of specific medications
Lack of awareness related to the disease
This research report encompasses precise assessment of the market with the help of comprehensive qualitative insights and supportable prognoses regarding market size, consumption and production. The projections presented in the report have been derived using proven research methodologies and assumptions. It does so by means of comprehensive qualitative insights, historical statistics, and verifiable predictions about market revenue and sales.
The rapidly budding threat owed to the eruption of COVID-19 is impacting lives, communities, businesses, and industries across the globe. With businesses shuttered, flights grounded, COVID-19 is about to affect the global economy in different ways such as by directly upsetting production and demand, by generating supply chain disruption, and by its financial impact on firms and financial markets. Therefore, this report covers COVID-19 outbreak impact analysis on the Pheochromocytoma market under the research study. The market estimates offered in the report are the outcome of in-depth extensive secondary research, primary interviews and in-house professional assessments. These market evaluations have been measured by reviewing the impact of numerous social, political and economic factors coupled with recent market dynamics affecting the Pheochromocytoma market growth.
The global Pheochromocytoma market is characterized by the presence of numerous small as well as medium scale companies. These players are largely focused towards forward integration via raw material production, product manufacturing, and distribution across various industry verticals. The report recognizes numerous crucial manufacturers of the market. This research study aids to comprehend the strategies and associations that companies are converging to survive in this competitive marketplace. This report assists in understanding footprints of the manufacturers with the help of their global revenue, production, capacity and average selling price analysis for period 2016-2027.
Major manufacturers analysed under this study comprises:
Pfizer Inc. (US)
Teva Pharmaceutical Company Limited (Israel)
Zydus Cadila (India)
Novartis AG (Switzerland)
Curium Pharma (UK)
Jubilant Cadista (US)
AstraZeneca (UK)
Mylan N.V. (US)
Apotex Inc. (Canada)
Reddy's Laboratories Ltd (India)
Lupin (India)
Glenmark Pharmaceuticals Limited (India)
This report delivers market breakdown and its revenue, consumption, production analysis and projections by categorizing it depending on parameters such as type, application/end-user, and region. This research report delivers the analysis and prognosis of revenue, production, price, market share and growth trend for different products such as:
By Treatment Type
Alpha-Blockers:
Beta Blockers:
Surgery:
Radionuclide Treatment:
Others:
By End-User
Hospitals and Clinics:
Research and Academic Institutes:
Others:
Regional Analysis and Forecast
Further, this research study analyses market size, production, consumption and its advancement trends at global, regional, and country level for period 2016 to 2027 and covers following region in its scope:
North America
? U.S.
? Canada
Europe
? Germany
? U.K.
? Italy
? France
? Rest of EU
Asia Pacific
? China
? India
? Japan
? Southeast Asia
? Rest of APAC
Central & South America
? Brazil
? Argentina
? Rest of Central & South America
Middle East and Africa
? UAE
? Saudi Arabia
? Rest of MEA
Request Customization
Get a Sample
Get a Sample
Request Customization